Antineoplastic 5-Fluorouracil CAS 51-21-8 Raw Materials Powder

CAS: 51-21-8

MF: C4H3FN2O2

Specification​: 99% min 5-Fluorouracil Powder

Sample: 5-Fluorouracil Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

5-Fluorouracil Powder Usage and Synthesis .

5-Fluorouracil is an antimetabolite of the pyrimidine class, which is a commonly used chemotherapeutic drug in clinical practice. It can inhibit the growth of cancer cells by preventing the formation of thymine and inhibiting DNA biosynthesis.

It is clinically used for the treatment of gastrointestinal tumors, such as gastric cancer, intestinal cancer, liver cancer, etc. It is also effective for breast cancer, ovarian cancer, lung cancer, bladder cancer, cervical cancer, pancreatic cancer, etc.

It is mainly used for heliokeratosis and senile keratosis, precancerous dermatitis, single and multiple superficial basal cell carcinoma, cancerous stage after radiation skin disease damage, and superficial basal cell carcinoma.

Application/Function of 5-Fluorouracil Powder.

5-Fluorouracil is first transformed into 5-fluoro-2-deoxyuracil nucleotide in the body, which inhibits thymine nucleotide synthase and blocks the transformation of uracil deoxyribonucleotide into thymine deChemicalbook oxygen nucleotide, thus affecting DNA biosynthesis. At the same time, it can adhere to RNA and achieve direct inhibition of RNA synthesis by blocking the incorporation of uracil and orotate into RNA.

It is an antitumor agent and is also used in the synthesis of fluorocytosine. 5-Fluorouracil is used in biochemical studies to study rice and wheat spike differentiation, genetic metabolism determination, and plant growth and development studies.

It is used in the treatment of digestive system cancer, head and neck cancer, gynecological cancer, lung cancer, liver cancer, bladder cancer and skin cancer

This drug is mainly catabolized in the liver, and most of it is dissolved into carbon dioxide and excreted from respiration, and very little is excreted by urine. After oral administration, its absorption varies greatly; after intravenous administration, its plasma concentration decreases quickly within two hours;

it can reach the cerebrospinal fluid within 30 minutes after sedation and be maintained for three hours; the toxicity of continuous intravenous drip is less than that of a single intravenous push; the efficacy of intravenous administration is also higher than that of oral administration.

Fluorouracil is more toxic to proliferating cells than to nonproliferating cells, but has no significant cell cycle specificity. Resistance to fluorouracil can be the result of a lack of enzymes essential for active action or an increase in the activity of thymidylate synthase.

It is used clinically for adjuvant chemotherapy and palliative treatment of breast cancer, gastrointestinal tract carcinoma, ovarian cancer and primary bronchopulmonary adenocarcinoma; it is also a chemotherapeutic agent for the treatment of malignant staphyloma, chorioepithelial carcinoma, plasma membrane cavity carcinoma effusion bladder cancer and head and neck malignancies and hepatocellular carcinoma.

Dermatologically, 5-Fluorouracil 5% ointment is used externally for the treatment of actinic keratosis, heliolipitis, Bowen's disease, Kaila proliferative erythema, Bowen-like papulosis, acanthosis, vitiligo, mossy amyloidosis, disseminated superficial sweat keratosis, common wart, flat wart, psoriasis, staining dry skin disease, superficial basal cell epithelioma, etc.; intra-dermal injection is used for the treatment of keratoacanthoma, keloid scar, etc.

Production method of 5-Fluorouracil Powder .

Because of the unstable absorption of fluorouracil, it is not routinely administered orally (oral formulations are available in Europe). It is usually administered intravenously. It can also be administered transarterially in order to reach the tumor directly (e.g., through the hepatic artery in the case of liver metastases) and can be injected directly into the exudate of the body cavity (e.g., ovarian cancer). The plasma half-life after intravenous injection is 7.5 to 10 minutes, and unchanged drug is no longer detectable in the plasma after 3 hours. Intracellular drug levels persist longer.

The use of methotrexate before this drug increases the formation of 5-fluorouracil nucleotides by increasing the intracellular levels of phosphoribosyl pyrophosphate. Allopurinol modifies the action of fluorouracil and its metabolite, allopurindiol, inhibits orotate phosphate ribosyltransferase, which reduces toxicity and may improve the therapeutic index.

Thymidine and other nucleosides increase the binding of fluorouracil to RNA, and thymidine delays the breakdown of fluorouracil via dihydropyrimidine dehydrogenase. However, this combination has not significantly improved clinical outcomes to date.